24/7 Market News Snapshot 14 May, 2025 – Atossa Therapeutics, Inc. Common Stock (NASDAQ:ATOS)

May 14, 2025

DENVER, Colo., 14 May, 2025 (www.247marketnews.com) – (NASDAQ:ATOS) are discussed in this article.
Atossa Therapeutics, Inc. (NASDAQ:ATOS) has experienced a notable surge in its stock price, which opened at $0.93 and has risen to $1.06, marking an increase of approximately 19.1%. This upswing follows a previous closing price of $0.89, reflecting a heightened level of investor interest and engagement, as evidenced by the current trading volume of 1.22 million shares. Investors and analysts are encouraged to observe potential resistance levels around $1.10 and support at approximately $1.00, with ongoing volume trends playing a critical role in predicting future price movements.

In conjunction with the stock price activity, Atossa has shared promising results from the Phase 2 Endocrine Optimization Pilot (EOP) sub-study, a vital part of the innovative I-SPY 2 TRIAL. This study evaluated the effectiveness of low-dose oral (Z)-endoxifen in patients with stage II/III estrogen-receptor-positive (ER+), HER2-negative breast cancer. Impressively, the study achieved a 95% completion rate, with 19 out of 20 participants meeting over 75% of the planned dosing, far exceeding the expected threshold.

The preliminary findings showcase significant anti-proliferative activity, with a median Ki-67 reduction from 10.5% at baseline to 5% by Week 3, and 65% of patients reaching Ki-67 levels of 10% or less. Additionally, a notable reduction in tumor size was documented, with a 77.7% decrease in median functional tumor volume and a 36.8% reduction in the longest tumor diameter. While no participants reached a pathologic complete response (pCR), Dr. Steven Quay, President and CEO of Atossa, remains optimistic, stressing the importance of exploring higher dosages of (Z)-endoxifen for optimal outcomes.

Atossa is also advancing its commitment to breast cancer treatment by enrolling participants in an I-SPY 2 cohort that will further investigate the efficacy of (Z)-endoxifen at a 40 mg daily dosage, both alone and in conjunction with the CDK4/6 inhibitor abemaciclib, with results expected in 2026. This strategic initiative reinforces Atossa’s dedication to enhancing treatment options for patients and advancing scientific understanding in the field of breast cancer therapy.

Related news for (ATOS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.